Condition: Diabetic Retinopathy (DR) · Sponsor: Artelus AI
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
This description comes directly from the study's public registry record.
Jeanne Champion, Primary Site Coordinator Oxford · 9192347003 · Jeanne@ncophth.com
Adriana Valencia, Site Coordinator Raleigh · 9192347406 · Adriana@ncophth.com
Always discuss trial participation with your own doctor first.
| New Century Ophthalmology - Oxford | Oxford, North Carolina, United States | Recruiting |
| New Century Ophthalmology - Raleigh | Raleigh, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07222293